These outcomes reinforce the role of SGLT2 inhibitors in the long-term management of heart failure, demonstrating their effectiveness in preventing serious complications like stroke, myocardial infarction, and cardiovascular death [37]. The gene discussed is SLC5A2; the disease is heart failure.